AMGN
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FAMGN.O%2Fkey-developments%2Farticle%2F2452819&ei=oIaaUtD9BYSQ0QGK1wE&usg=AFQjCNG6QmOpLL5MJVDyX4wTTf31ki1arw
Amgen, Inc. And Watson Pharmaceuticals, Inc. Announces Collaboration To Develop And Commercialize Oncology Biosimilars
Monday, 19 Dec 2011 04:00pm EST
Amgen, Inc. and Watson Pharmaceuticals, Inc. announced that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines. Under the terms of the agreement, Amgen will assume primary responsibility for developing, manufacturing and initially commercializing the oncology antibody products. Watson will contribute up to $400 million in co-development costs over the course of development, including the provision of development support, and will share product development risks. In addition, Watson will contribute in the commercialization and marketing of products in competitive specialty and generic markets, including to help effectively manage the lifecycle of the biosimilar products.Â 
